




SPACS 2022

CANCER CAPITAL CORP
Rank 15 of 21





SPACS 2022

CANCER CAPITAL CORP
Rank 15 of 21

The relative strengths and weaknesses of CANCER CAPITAL CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CANCER CAPITAL CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 50% points. The greatest weakness of CANCER CAPITAL CORP is the variable Other Assets, reducing the Economic Capital Ratio by 254% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,020%, being 419% points below the market average of -601%.

Input Variable	Value in 1000 USD
Assets, Current	0.062
Assets, Non-Current	0
General And Administrative Expense	18
Liabilities, Current	369
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-18
Other Revenues	0
Professional Fees	0

Output Variable	Value in 1000 USD
Assets	0.062
Liabilities	369
Expenses	18
Revenues	0
Stockholders Equity	-369
Net Income	-37
Comprehensive Net Income	-37
Economic Capital Ratio	-1,020%